| Range: | 13.235-18.05 | Vol Avg: | 2930576 | Last Div: | 1 | Changes: | 0.37 |
| Beta: | 2.02 | Cap: | 3.11B | Currency: | USD | Exchange: | NYSE |
| Sector: | Real Estate | IPO: | Wed Jan 04 2017 | Empoloyees: | 90 | ||
| CUSIP: | 700517105 | CIK: | 0001617406 | ISIN: | US7005171050 | Country: | US |
| CEO: | Mr. Thomas Jeremiah Baltimore Jr. | Website: | https://www.pkhotelsandresorts.com | ||||
PK 15.05 Stock Price Park Hotels & Resorts Inc.
Park is the second largest publicly traded lodging REIT with a diverse portfolio of market-leading hotels and resorts with significant underlying real estate value. Park's portfolio currently consists of 60 premium-branded hotels and resorts with over 33,000 rooms primarily located in prime city center and resort locations.
Stock Details
Positive 0.60
Park Hotels & Resorts Inc. Reinstates 2024 Earnings Guidance; Operators and Union Finalize Long-Term Labor Agreements in Hawaii, Seattle and Boston Ending Nearly Six-Weeks of Strike Activity at Four Hotels
TYSONS, Va., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Park Hotels & Resorts Inc. (“Park” or the “...
globenewswire.com·Mon Nov 11 2024
Neutral -0.10
UNITE HERE Park Hotels Monitoring Website Now Includes “Review Summaries”
HONOLULU--(BUSINESS WIRE)--Park Hotels Capex Problems now includes excerpts from TripAdvis...
businesswire.com·Thu Oct 31 2024
Positive 0.28
Park Hotels & Resorts Inc. (PK) Q3 2024 Earnings Call Transcript
Park Hotels & Resorts Inc. (NYSE:PK ) Q3 2024 Earnings Conference Call October 30, 2024 11...
seekingalpha.com·Wed Oct 30 2024
Positive 0.20
Park Hotels & Resorts (PK) Matches Q3 FFO Estimates
Park Hotels & Resorts (PK) came out with quarterly funds from operations (FFO) of $0.49 pe...
zacks.com·Tue Oct 29 2024
Neutral 0.00
Park Hotels & Resorts Inc. Reports Third Quarter 2024 Results
TYSONS, Va., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Park Hotels & Resorts Inc. (“Park” or the “...
globenewswire.com·Tue Oct 29 2024
Positive 0.20
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
-- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of th...
globenewswire.com·Thu Sep 26 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow